Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer

Matsuura Kanji

Kimura Tomoki

Kashiwado Kozo

Fujita Kazushi

Akagi Yukio

Yuki Shintarou

Murakami Yuji

Wadasaki Koichi

Monzen Yoshio

Ito Atsushi

Kagemoto Masayuki

Mori Masaki

Ito Katsuhide

Nagata Yasushi

International Journal of Clinical Oncology

We aimed to evaluate the feasibility and efficacy of hypofractionated involved-field radiation therapy (IFRT) omitting elective nodal irradiation (ENI) with concurrent chemotherapy for locally advanced non-small-cell lung cancer (NSCLC). Between July 2004 and July 2006, ten patients with locally advanced NSCLC were included in this study. One had stage IIIA and 9 had stage IIIB disease. The treatment consisted of IFRT in fractions of 2.5 Gy and weekly carboplatin (CBDCA)/paclitaxel (PTX). Hypofractionated IFRT with a median total dose of 65 Gy with median percent total lung volume exceeding 20 Gy (V20) of 20.2%, and a median of five courses of chemotherapy with weekly CBDCA (area under the curve, 1.5-2.0)/PTX (30-35 mg/m(2)) were given to all patients. The median survival time and the 1-, 2-, and 3-year overall survival rates were 29.5 months and 90.0%, 58.3%, and 43.8%, respectively. No elective nodal failure was encountered during the median follow up of 18.2 months. No acute or late toxicities of grade 3 or worse were observed. No in-field recurrence occurred in the group with a total dose of 67.5 Gy or more, but there was such recurrence in 83.3% of those in the group with less than 67.5 Gy. Hypofractionated IFRT with weekly CBDCA/PTX was a feasible treatment regimen. Hypofractionated IFRT with a total dose of 67.5 Gy or more could be a promising modality to improve the treatment results in patients with locally advanced NSCLC.

Involved-field radiation therapy (IFRT)

Elective nodal irradiation (ENI)

Three-dimensional conformal radiation therapy (3DCRT)

Non-small-cell lung cancer (NSCLC)

Carboplatin (CBDCA)

Paclitaxel (PTX)

Medical sciences [ 490 ]

eng

Springer Tokyo

Copyright (c) 2009 Springer

The original publication is available at www.springerlink.com

[ISSN] 1341-9625

[DOI] 10.1007/s10147-009-0889-0

[NCID] AA11086579

[DOI] http://dx.doi.org/10.1007/s10147-009-0889-0